Clinical Trial Update: Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating pembrolizumab plus lenvatinib for unresectable cutaneous angiosarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Center, Japan | Conditions: Angiosarcoma of Skin, Angiosarcoma Metastatic | Phase 2 | Status: RECRUITING